We noted remarkably high 68Ga-MY6349 uptake in prostate cancer; consequently, Trop2-targeted ADCs could present a new therapeutic strategy for mCRPC that is resistant to either ARSIs or Pluvicto. The gene discussed is TACSTD2; the disease is prostate carcinoma.